دورية أكاديمية

Susceptibility of Mice Deficient in the MHC Class II Transactivator to Infection with Mycobacterium tuberculosis.

التفاصيل البيبلوغرافية
العنوان: Susceptibility of Mice Deficient in the MHC Class II Transactivator to Infection with Mycobacterium tuberculosis.
المؤلفون: Repique, C. J., Li, A., Brickey, W. J., Ting, J. P. Y., Collins, F. M., Morris, S. L.
المصدر: Scandinavian Journal of Immunology; Jul2003, Vol. 58 Issue 1, p15-22, 8p
مصطلحات موضوعية: MYCOBACTERIAL diseases, LUNG diseases, TUBERCULOSIS, IMMUNITY, INTERFERONS
مستخلص: Abstract Major histocompatibility complex (MHC) class II antigen presentation and subsequent CD4+ T-cell activation are critical for acquired immunity to Mycobacterium tuberculosis infection. MHC class II gene expression is primarily controlled by the master transactivator CIITA protein. Without functional CIITA protein, MHC class II expression is lost, impairing immune responses and increasing susceptibility to infection. In this study, we compared protective immune responses of CIITA-deficient mice and wild-type C57BL/6 controls with low dose aerosol M. tuberculosis infection. After aerogenic challenge, CIITA–/– mice failed to limit mycobacterial growth (2.5 and 2.0 log10 > WT lung and spleen CFUs, respectively, at day 58). Lung histopathology involved extensive necrosis, severe pneumonitis and overwhelming inflammation in the gene knockout mice. Mean survival time for CIITA–/– mice was significantly reduced (57 versus >300 days for WT). This extreme sensitivity to tuberculous infection was largely attributed to the absence of CD4+ cells. Flow cytometric studies detected virtually no CD4+ cells in CIITA–/– mouse spleens after infection versus elevated numbers in WT spleens. Failed CD4+ T-cell expansion markedly reduced interferon-γ (IFN-γ production in CIITA–/– mice versus WT controls. These results suggest the necessity of a functional CIITA pathway for controlling tuberculous infections and that interventions targeting CIITA expression may be useful antimycobacterial therapeutics. [ABSTRACT FROM AUTHOR]
Copyright of Scandinavian Journal of Immunology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:03009475
DOI:10.1046/j.1365-3083.2003.01266.x